I understand that it is extremely difficult to predict how efficacious a drug will be in humans based upon invitro studies. However, I think B has a few things going for it in this regard. First, the drug has proven to be very effective as an antibiotic in humans already via IV and other methods of introduction to humans. Second, the Selectivity Index of 426 is another indicator that it has a a strong possibility of translating its effectiveness in antiviral activity to invivo. Two very big indicators if you ask me. I suspect that Leo is working his tail off to get the trials up an running based upon these signposts, but I also hope he is negotiating partnerships that will allow rapid commercialization once the proof is in the pudding....IMHO.